Alnylam to Webcast Conference Call Discussing Third Quarter 2014 Financial ...
... an RNAi therapeutic targeting angiotensinogen (AGT) for the treatment of hypertensive disorders of pregnancy (HDP), including preeclampsia; ALN-GO1, an RNAi therapeutic targeting glycolate oxidase (GO) for the treatment of primary hyperoxaluria ...
MarketWatch - Wed, 29 Oct 2014 13:04

Alnylam Appoints Pushkal Garg, M.D., Senior Vice President, Clinical ...
... an RNAi therapeutic targeting angiotensinogen (AGT) for the treatment of hypertensive disorders of pregnancy (HDP), including preeclampsia; ALN-GO1, an RNAi therapeutic targeting glycolate oxidase (GO) for the treatment of primary hyperoxaluria ...
MarketWatch - Wed, 29 Oct 2014 05:04

Poster Highlights Rapid and Durable Effect of DCR-PH1 in Mouse Model of PH1
WATERTOWN, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development of RNAi-based therapeutics, presented data from its preclinical program in primary hyperoxaluria type 1 (PH1) in a poster session at the ...
Business Wire (press release) - Tue, 14 Oct 2014 14:22

Dicerna Presents Preclinical Data for Investigational RNAi Therapeutic DCR ...
MarketWatch - Tue, 14 Oct 2014 14:36

Alnylam Presents New Clinical and Pre-Clinical Data on RNAi Therapeutics at ...
DigitalJournal.com - Tue, 14 Oct 2014 05:00

Oxabact® Granted EMA Orphan Drug Designation for Treatment of SBS
OxThera is currently pursuing a complete clinical development program in the EU and in the US for the treatment of patients suffering from Primary Hyperoxaluria. Oxabact® previously holds orphan drug designations in the EU and the US for the treatment ...
SYS-CON Media (press release) - Tue, 23 Sep 2014 00:30

Alnylam Reveals Positive Data from its Pipeline Candidates
The candidate is currently being developed in a phase II study in ATTR patients suffering from TTR cardiac amyloidosis. Initial data from the study is expected next month. Preclinical data on ALN-GO1 being developed for the treatment of primary ...
Zacks.com - Wed, 15 Oct 2014 12:30



Biochemists solve 'address problem' in cells that leads to lethal kidney disease
PH1 — short for primary hyperoxaluria 1 — starts at birth and is usually fatal for patients who do not receive both kidney and liver transplants. Approximately half of those with the disease have kidney failure by age 15. Koehler has presented her ...
EurekAlert (press release) - Thu, 25 Sep 2014 14:45

Alnylam Launches Alnylam AssistTM, Dedicated to Providing Support to Patients ...
... an RNAi therapeutic targeting angiotensinogen (AGT) for the treatment of hypertensive disorders of pregnancy (HDP), including preeclampsia; ALN-GO1, an RNAi therapeutic targeting glycolate oxidase (GO) for the treatment of primary hyperoxaluria ...
Finances.com - Mon, 20 Oct 2014 05:00

Familial mixed nephrocalcinosis as a cause of chronic kidney failure: two case ...
IntroductionNephrocalcinosis consists of the deposition of calcium salts in the renal parenchyma and is considered the mixed form when it involves the renal cortex and medulla. The main etiological agents of this condition are primary ...
7thSpace Interactive (press release) - Mon, 27 Oct 2014 02:11


1  2  3  4  5  6  7    ->


We do not evaluate or guarantee the accuracy of any content in this site. Click here for the full disclaimer.

Last update: September 2014